- Home
- BRT vs AQST Comparison
BRT vs AQST Comparison
Compare BRT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- AQST
- Stock Information
- Founded
- BRT 1972
- AQST 2004
- Country
- BRT United States
- AQST United States
- Employees
- BRT N/A
- AQST N/A
- Industry
- BRT Real Estate Investment Trusts
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- AQST Health Care
- Exchange
- BRT Nasdaq
- AQST Nasdaq
- Market Cap
- BRT 330.2M
- AQST 285.4M
- IPO Year
- BRT N/A
- AQST 2018
- Fundamental
- Price
- BRT $17.58
- AQST $2.97
- Analyst Decision
- BRT Strong Buy
- AQST Strong Buy
- Analyst Count
- BRT 3
- AQST 8
- Target Price
- BRT $22.17
- AQST $10.38
- AVG Volume (30 Days)
- BRT 26.8K
- AQST 1.4M
- Earning Date
- BRT 03-11-2025
- AQST 03-04-2025
- Dividend Yield
- BRT 5.67%
- AQST N/A
- EPS Growth
- BRT N/A
- AQST N/A
- EPS
- BRT N/A
- AQST N/A
- Revenue
- BRT $96,743,000.00
- AQST $58,900,000.00
- Revenue This Year
- BRT N/A
- AQST $18.44
- Revenue Next Year
- BRT $5.73
- AQST N/A
- P/E Ratio
- BRT N/A
- AQST N/A
- Revenue Growth
- BRT 1.95
- AQST 22.56
- 52 Week Low
- BRT $15.21
- AQST $2.24
- 52 Week High
- BRT $20.22
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- BRT 50.76
- AQST 34.27
- Support Level
- BRT $16.84
- AQST $2.87
- Resistance Level
- BRT $17.65
- AQST $3.17
- Average True Range (ATR)
- BRT 0.43
- AQST 0.14
- MACD
- BRT 0.07
- AQST 0.02
- Stochastic Oscillator
- BRT 74.00
- AQST 9.30
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is primarily focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.